Over the last 12 months, Nuvation Bio insiders reported 1 buy totaling $118K and 3 sales totaling $1.4M across SEC Form 4 filings. 75% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Markel StacyCHIEF PEOPLE OFFICER · O | ▼ Sale | 125,000 | $6.03 | $753K | -79.3% | plan |
| Jun 23, 2026 | Wentworth KerryCHIEF REGULATORY OFFICER · O | ▼ Sale | 63,000 | $6.02 | $379K | -54.3% | plan |
| Jun 23, 2026 | Sauvage PhilippeChief Financial Officer · O | ▼ Sale | 47,668 | $6.01 | $286K | -79% | plan |
| Jun 9, 2026 | Mashal RobertD | ▲ Buy | 25,000 | $4.73 | $118K | +12.5% | indirect |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NUVB feed.